The clinical landscape of ADCs in both heme and solid cancers has grown to nearly 600 clinical trials incorporating nearly 60 ADCs utilizing payload-warhead of various mechanisms such as tubulin inhibitors, DNA damaging, topoisomerase inhibition, ENA polymerase II inhibitors. Although the heme cancers, including leukemias and lymphomas are the predominant targets of the majority of ADCS, the solid cancers of breast, colorectal, lung, prostate, ovarian, urothelial system are increasing being targeted by the next generation ADCs. In 2018, there has been an increased progression of the ADCs in late stage clinical trials and this has increased the possibility of a greater number of ADCs gaining FDA approval and reaching to cancer patients.
Advertisement #4
